Oric Pharmaceuticals Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

ORIC$9.23+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Statements of Stockholders’ Equity

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · Accumulated · Accumulated Other Comprehensive · TotalStockholders'
	Shares	Amount	Capital	Deficit	Income (Loss)	Equity
Balance at December 31, 2023	54,865,553	$6	$658,751	$(434,927)	$258	$224,088
Issuance of common stock, net	12,500,000	1	124,831	—	—	124,832
Exercise of common stock options	51,540	—	198	—	—	198
Issuance of common stock upon vesting of RSUs	3,245	—	—	—	—	—
Stock-based compensation expense	—	—	4,958	—	—	4,958
Unrealized loss on investments	—	—	—	—	(420)	(420)
Net loss	—	—	—	(25,011)	—	(25,011)
Balance at March 31, 2024	67,420,338	$7	$788,738	$(459,938)	$(162)	$328,645
Exercise of common stock options	71,936	—	293	—	—	293
Issuance of common stock upon vesting of RSUs	10,780	—	—	—	—	—
Issuance of common stock from ESPP	169,249	—	523	—	—	523
Stock-based compensation expense	—	—	4,996	—	—	4,996
Unrealized loss on investments	—	—	—	—	(94)	(94)
Net loss	—	—	—	(31,963)	—	(31,963)
Balance at June 30, 2024	67,672,303	$7	$794,550	$(491,901)	$(256)	$302,400
Exercise of pre-funded warrants	2,857,104	—	—	—	—	—
Exercise of common stock options	26,435	—	126	—	—	126
Issuance of common stock upon vesting of RSUs	3,341	—	—	—	—	—
Stock-based compensation expense	—	—	5,056	—	—	5,056
Unrealized gain on investments	—	—	—	—	978	978
Net loss	—	—	—	(34,566)	—	(34,566)
Balance at September 30, 2024	70,559,183	$7	$799,732	$(526,467)	$722	$273,994

STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands, except share amounts)

Common Stock · AdditionalPaid-in · Accumulated · Accumulated Other Comprehensive · TotalStockholders'
	Shares	Amount	Capital	Deficit	Income (Loss)	Equity
Balance at December 31, 2022	45,089,537	$5	$557,867	$(334,230)	$(1,291)	$222,351
Exercise of common stock options	16	—	—	—	—	—
Issuance of common stock upon vesting of RSUs	1,662	—	—	—	—	—
Stock-based compensation expense	—	—	3,614	—	—	3,614
Unrealized gain on investments	—	—	—	—	792	792
Net loss	—	—	—	(23,945)	—	(23,945)
Balance at March 31, 2023	45,091,215	$5	$561,481	$(358,175)	$(499)	$202,812
Issuance of common stock and pre-funded warrants, net	9,285,710	1	84,773	—	—	84,774
Issuance of common stock upon vesting of RSUs	9,308	—	—	—	—	—
Issuance of common stock from ESPP	145,938	—	400	—	—	400
Stock-based compensation expense	—	—	3,825	—	—	3,825
Unrealized loss on investments	—	—	—	—	(68)	(68)
Net loss	—	—	—	(22,944)	—	(22,944)
Balance at June 30, 2023	54,532,171	$6	$650,479	$(381,119)	$(567)	$268,799
Exercise of common stock options	7,169	—	31	—	—	31
Issuance of common stock upon vesting of RSUs	1,375	—	—	—	—	—
Stock-based compensation expense	—	—	3,864	—	—	3,864
Unrealized gain on investments	—	—	—	—	198	198
Net loss	—	—	—	(25,478)	—	(25,478)
Balance at September 30, 2023	54,540,715	$6	$654,374	$(406,597)	$(369)	$247,414

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.